Introduction
Abemaxen 200 mg (Abemaciclib) is a maximum-strength, targeted oncology medication classified as a selective CDK4 and CDK6 inhibitor. Manufactured by Everest Pharmaceuticals Ltd. and supplied globally by Onco Solution, Abemaxen is a cornerstone therapy for advanced, high-risk breast cancers. It works by blocking specific cellular proteins that signal cancer cells to grow and divide rapidly. The 200 mg strength provides the critical dosage required for specialized monotherapy regimens, offering a powerful, precise approach to slowing disease progression and improving patient outcomes.
Indications
Abemaxen 200 mg (Abemaciclib) is indicated for:
- HR+/HER2- Advanced or Metastatic Breast Cancer (Monotherapy): As a single agent for adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer whose disease has progressed following endocrine therapy and prior chemotherapy in the metastatic setting.
- HR+/HER2- Early & Advanced Breast Cancer (Combination/Dose Titration): Used in combined regimens with endocrine therapies (such as aromatase inhibitors or fulvestrant) or for specific patient titration schedules requiring a 200 mg baseline dose under expert clinical guidance.
Pharmacology
Abemaciclib, the active ingredient in Abemaxen, is an oral, selective, small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6).
- Mechanism: It prevents the phosphorylation of the Retinoblastoma (Rb) protein, blocking the progression of the cell cycle from the G1 phase to the S phase.
- Tumor Suppression: This cell-cycle arrest effectively induces cellular senescence or apoptosis (cell death) in estrogen receptor-positive breast cancer lines. Abemaxen exhibits higher selectivity for CDK4 than other inhibitors in its class and is highly brain-penetrant, making it clinically active against intracranial metastases.
Dosage & Administration
Oral Administration for Adults:
- Monotherapy Standard Dose: 200 mg taken orally twice daily.
- Administration: Tablets should be taken at approximately the same time each day (usually morning and evening), with or without food.
- Method: Swallow tablets whole with a glass of water. Do not chew, crush, or split the tablets.
- Missed Dose: If a patient vomits or misses a dose, the next dose should be taken at its regularly scheduled time; a double dose should not be taken.
Drug Interactions
- Strong CYP3A4 Inhibitors: Co-administration (e.g., Ketoconazole, Claritromycin) increases abemaciclib exposure. Avoid concomitant use; if unavoidable, the dose of Abemaxen must be reduced significantly.
- Strong CYP3A4 Inducers: Avoid co-administration (e.g., Rifampin, Phenytoin) as they can drastically decrease Abemaxen plasma levels and minimize therapeutic efficacy.
- Grapefruit Products: Avoid consuming grapefruit juice or grapefruit products, as they alter drug metabolism and increase toxicity risks.
Contraindications
- Hypersensitivity: Known severe hypersensitivity to Abemaciclib or any inactive ingredients listed in the formulation.
- Pregnancy: Categorized as a known risk to fetal development.
Side Effects
Patients receiving Abemaxen 200 mg may experience:
- Gastrointestinal: Severe diarrhea (most common, usually occurring within the first month of therapy), nausea, vomiting, and decreased appetite.
- Hematological: Neutropenia, leukopenia, anemia, and thrombocytopenia.
- Systemic: Fatigue, increased susceptibility to infections (such as upper respiratory tract infections), abdominal pain, and dizziness.
- Vascular: Increased risk of venous thromboembolism (VTE) and deep vein thrombosis (DVT).
Pregnancy & Lactation
- Pregnancy: Can cause fetal harm. Females of reproductive potential must use effective non-hormonal contraception during treatment and for at least 3 weeks after the final dose.
- Lactation: Advise lactating women not to breastfeed during treatment and for at least 3 weeks after the last dose due to safety concerns for the infant.
Precautions & Warnings
- Diarrhea Management: Severe diarrhea can lead to dangerous dehydration. At the first sign of loose stools, patients must immediately start antidiarrheal therapy (e.g., loperamide) and increase fluid intake.
- Hematology Monitoring: Complete Blood Counts (CBC) must be monitored prior to the start of therapy, every 2 weeks for the first 2 months, and monthly thereafter.
- Hepatotoxicity: Monitor liver function tests (ALT, AST, Bilirubin) closely. Interrupt or reduce the dose if severe elevations occur.
- Interstitial Lung Disease (ILD): Monitor for pulmonary symptoms such as cough or dyspnea. Permanently discontinue if severe ILD/pneumonitis is confirmed.
Use in Special Populations
- Hepatic Impairment: For patients with severe hepatic impairment (Child-Pugh Class C), the dosing frequency must be reduced (e.g., once daily or adjusted by a specialist).
- Geriatric Use: No overall differences in safety or effectiveness have been observed compared to younger patients, but closer monitoring for toxicities is recommended due to potential age-related organ decline.
Overdose Effects
Overdose may result in severe diarrhea, profound bone marrow suppression (severe neutropenia), and extreme fatigue. Treatment consists of immediate discontinuation of the medication and aggressive supportive, symptomatic therapies.
Storage
- Condition: Store at controlled room temperature (15°C to 30°C).
- Protection: Keep the medication in its original blister packaging or container to protect it from moisture and direct light. Keep out of reach of children.
Supplier Information
Onco Solution is a premier global oncology medicine supplier dedicated to bridging the gap in advanced cancer care. We ensure secure, reliable, and authentic global distribution of breakthrough therapies like Abemaxen 200 mg. For medical quotes or wholesale inquiries, visit www.oncosolution.com.
Manufacturer Information
Abemaxen 200 mg is manufactured by Everest Pharmaceuticals Ltd., a leading high-tech pharmaceutical company based in Bangladesh, recognized for its strict adherence to international standards in the production of specialized generic oncology medications.
